The provision of optimal care for patients with FLT3-mutated AML is an increasingly complex process, particularly for community oncology clinicians. Compared with healthcare providers working in specialized, academic centers, these care providers have less extensive experience treating this rarer hematologic malignancy. Without targeted educational interventions, community oncology clinicians may struggle to integrate newer, FLT3 inhibitors appropriately into real-world settings and align their practices with their counterparts at dedicated, AML treatment centers. By engaging in a combination of small-group and case-based education, these healthcare providers can improve their ability to perform molecular testing, differentiate among approved FLT3 inhibitors, and modify treatment strategies in response to treatment-related adverse events. These initiatives can additionally enhance community oncologists ability to deliver supportive care and identify patients who may require a transfer to academic centers for further management. Ultimately, by improving collaboration between members of the multidisciplinary team and across healthcare systems, community oncologists can ensure that patients with FLT3-mutated AML receive convenient, high-quality care consistent with clinical practice guidelines and expert practice.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Pricing
All courses included · from $18.75/mo
Courses are included in the subscription; some are also sold individually.
| Student Flex | $18.75/mo |
| Professional Flex | $60/mo |
| Student 3-Year | $100 |
| Student 2-Year | $112.50 |
+4 more plans
Collected from the provider’s public pages · source
Specialties served/covered
- Cardiovascular Disease
- Communication & Shared Decision-Making
- Dermatology
- Endocrinology, Diabetes & Metabolism
- Family Medicine
- Gastroenterology
- Gastrointestinal Surgery
- General & Adult Psychiatry
- General Internal Medicine
- Gynecologic Oncology
- Health Equity & Inclusion
- Hematology
- Maternal-Fetal Medicine
- Medical Leadership & Administration
- Medical Oncology
- Mood & Anxiety Disorders
- Nephrology
- Neurocritical Care
- Neurodevelopmental Disabilities
- Neurology
- Neuroradiology
- Nuclear Medicine
- Obstetrics & Gynecology
- Ophthalmology
- Plastic & Reconstructive Surgery
- Practice Management & Ethics
- Pulmonary Disease
- Sleep Medicine
- Surgical Oncology
- Thoracic Anesthesia
- Urological Oncology
- Anesthesiology
- Cardio-Vascular
- Cross-Specialty
- Emergency & Critical Care
- GI & Liver
- Infectious Disease
- Internal Medicine
- Medical Subspecialties
- Neurology
- Ob/Gyn
- Oncology & Hematology
- Primary care
- Psychiatry
- Radiology
- Surgery
- Urology
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- Conference / congress
- includes Case-based learning
- Credit · Up to 1 credit
- Commercial Support
-
ReleasedApr 27, 2026
-
Last day to claim creditApr 28, 2027 7 months left
-
Medscape, LLC Autumn Updates: Exploring Innovations in EGFR-Mutated NSCLC
-
PRIME Education, Inc. (PRIME®) Clinical Momentum: Advancements for Menin Inhibitors in NPM1-Mutated AML
-
Clinical Care Options, LLC (dba Decera Clinical Education) Management of a Patient With EGFR-Mutated NSCLC and Brain Metastases
-
Plexus Communications +1 Advancing EGFR-Mutated NSCLC Management Across Practice Settings: Evidence-Based Approaches to Testing, Treatment Selection, and Sequencing
-
Plexus Communications +1 Targeting CD19 for DLBCL and FL: Beyond CAR T-Cells
-
Plexus Communications +1 Advancing Clinical Expertise in CELMoDs: Transforming Multiple Myeloma Treatment
